09 Dec 2024
// PRESS RELEASE
30 Nov 2024
// PRESS RELEASE
03 Nov 2024
// PRESS RELEASE
Latest Content by PharmaCompass
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
About
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Attending
28-30 October, 2025
Pharma Live ExpoPharma Live Expo
Industry Trade Show
Not Confirmed
17-19 April, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Attending
28-30 October, 2025
Pharma Live ExpoPharma Live Expo
Industry Trade Show
Not Confirmed
17-19 April, 2025
CORPORATE CONTENT #SupplierSpotlight
09 Dec 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/10-releases/197-forbes
30 Nov 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/10-releases/191-ifoxa-release
03 Nov 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/10-releases/192-vicrista-release
22 Oct 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/9-news/190-top-exporters
29 Jun 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/10-releases/36-endoxyna-release
08 Jun 2024
// PRESS RELEASE
https://www.nanoalvand.com/index.php/en/blog-en/10-releases/36-endoxyna-release
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
About the Company : NanoAlvand, founded in 2011, is a knowledge-based company dedicated to the manufacturing of advanced, highly potent pharmaceutical products for both domestic & global markets. With a steadfast c...
Details:
Ifoxa (ifosfamide) is a cytotoxic drug that binds to DNA and inhibit DNA synthesis. Ifoxa is indicated for the treatment of malignant diseases.
Lead Product(s): Ifosfamide
Therapeutic Area: Oncology Brand Name: Ifoxa
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2024
Lead Product(s) : Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ifoxa® by NanoAlvand Enhances Chemotherapy with Improved Side Effect Profile
Details : Ifoxa (ifosfamide) is a cytotoxic drug that binds to DNA and inhibit DNA synthesis. Ifoxa is indicated for the treatment of malignant diseases.
Product Name : Ifoxa
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 30, 2024
Details:
Vicrista (vincristine sulphate) is a type of chemotherapy called a vinca alkaloid which interfere with microtubules and blocks cell growth by stopping mitosis. It is indicated for pediatric cancers.
Lead Product(s): Vincristine Sulfate
Therapeutic Area: Oncology Brand Name: Vicrista
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2024
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Introducing Vicrista® – A New Era in Pediatric Oncology
Details : Vicrista (vincristine sulphate) is a type of chemotherapy called a vinca alkaloid which interfere with microtubules and blocks cell growth by stopping mitosis. It is indicated for pediatric cancers.
Product Name : Vicrista
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 03, 2024
Details:
Endoxyna is a novel liquid formulation of cyclophosphamide, to replace the previous freeze-dried products. It is indicated for the treatment of cancer
Lead Product(s): Cyclophosphamide
Therapeutic Area: Oncology Brand Name: Endoxyna
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 29, 2024
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endoxyna®; A Crucial Medication with A Novel Solution Formulation
Details : Endoxyna is a novel liquid formulation of cyclophosphamide, to replace the previous freeze-dried products. It is indicated for the treatment of cancer
Product Name : Endoxyna
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 29, 2024
Details:
Pomavid, a high-quality version of pomalidomide. Pomavid® is a new generation medication for the treatment of multiple myeloma, a type of blood cancer.
Lead Product(s): Pomalidomide
Therapeutic Area: Oncology Brand Name: Pomavid
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2024
Lead Product(s) : Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pomavid®; Our Dedication to Shaping Hope
Details : Pomavid, a high-quality version of pomalidomide. Pomavid® is a new generation medication for the treatment of multiple myeloma, a type of blood cancer.
Product Name : Pomavid
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 07, 2024
Details:
Wellosia (ozanimod) is a S1P modulator, small molecule drug candidate, which is indicated for the treatment of relapsing forms of multiple sclerosis & moderately to severely active ulcerative colitis.
Lead Product(s): Ozanimod
Therapeutic Area: Neurology Brand Name: Wellosia
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2021
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wellosia®; Prioritizing our Patients' Well-Being
Details : Wellosia (ozanimod) is a S1P modulator, small molecule drug candidate, which is indicated for the treatment of relapsing forms of multiple sclerosis & moderately to severely active ulcerative colitis.
Product Name : Wellosia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2021
Regulatory Info :
Registration Country : Iran
Dosage Form : Film Coated Tablet
Brand Name : Xybrone
Dosage Strength : 250MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Film Coated Tablet
Brand Name : Xybrone
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Trisenal
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Leukaza
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Film Coated Tablet
Brand Name : Intyma
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Film Coated Tablet
Brand Name : Intyma
Dosage Strength : 4MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Bendanit
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Bendanit
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Alvocade
Dosage Strength : 3.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Dosage Form : Vial
Brand Name : Alvocade
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
ABOUT THIS PAGE
NanoAlvand is a supplier offers 28 products (APIs, Excipients or Intermediates).
Find a price of Abiraterone Acetate bulk offered by NanoAlvand
Find a price of Azacitidine bulk offered by NanoAlvand
Find a price of Bortezomib bulk offered by NanoAlvand
Find a price of Busulfan bulk offered by NanoAlvand
Find a price of Cabazitaxel bulk offered by NanoAlvand
Find a price of Carfilzomib bulk offered by NanoAlvand
Find a price of Caspofungin bulk offered by NanoAlvand
Find a price of Cladribine bulk offered by NanoAlvand
Find a price of Dactinomycin bulk offered by NanoAlvand
Find a price of Enzalutamide bulk offered by NanoAlvand
Find a price of Epoprostenol Sodium bulk offered by NanoAlvand
Find a price of Eribulin bulk offered by NanoAlvand
Find a price of Everolimus bulk offered by NanoAlvand
Find a price of Fludarabine Phosphate bulk offered by NanoAlvand
Find a price of Fluorouracil bulk offered by NanoAlvand
Find a price of Ibrutinib bulk offered by NanoAlvand
Find a price of Idarubicin Hydrochloride bulk offered by NanoAlvand
Find a price of Lenalidomide bulk offered by NanoAlvand
Find a price of Methotrexate bulk offered by NanoAlvand
Find a price of Mitoxantrone bulk offered by NanoAlvand
Find a price of Mycophenolic Acid bulk offered by NanoAlvand
Find a price of Ozanimod bulk offered by NanoAlvand
Find a price of Palbociclib bulk offered by NanoAlvand
Find a price of Plerixafor bulk offered by NanoAlvand
Find a price of Ruxolitinib Phosphate bulk offered by NanoAlvand
Find a price of Thiotepa bulk offered by NanoAlvand
Find a price of Tofacitinib Citrate bulk offered by NanoAlvand
Find a price of Vincristine Sulfate bulk offered by NanoAlvand